Sentences with phrase «amyloid hypothesis»
The "amyloid hypothesis" is a theory about the cause of certain diseases like Alzheimer's. It suggests that the accumulation of a protein called amyloid in the brain is responsible for the development of these diseases. According to this hypothesis, the buildup of amyloid disrupts brain function and leads to memory loss and other cognitive problems. Full definition
One of the biggest problems in Alzheimer's drug development is uncertainty over the so - called «amyloid hypothesis» — the proposed model that a buildup of a kind of plaque called amyloid - β in brain tissue is at the root of Alzheimer's and other dementia - related diseases.
fortune.com
The «amyloid hypothesis» figures that a buildup of brain plaque is what leads to the cognitive decline that Alzheimer's patients experience.
Unlike some of the promising treatments that have failed in 2017 that deal with the so - called «amyloid hypothesis» (the treatments target amyloid beta deposits in the brain that accumulate in people with Alzheimer's disease), approaches that try to prevent nerve cells from dying wouldn't have any impact on that buildup.
This idea of targeting beta amyloid deposits in the brain to clear them out is known as the «amyloid hypothesis.»
The amyloid hypothesis has already been put to the test and seen a few failures.
Genentech is one of the companies developing drugs that go after the amyloid hypothesis.
For one, Merck's now - failed BACE inhibitor was also acting on the amyloid hypothesis to prevent the protein from forming and keep the disease from progressing.
Solanezumab, a drug developed by Eli Lilly that also acts on the amyloid hypothesis, failed some key clinical trials, though the company is still testing it in the pre-clinical stages of the disease.
«The amyloid hypothesis became such a strong scientific orthodoxy that it began to be accepted on the basis of faith rather than evidence,» says Zaven Khachaturian, president of the non-profit campaign Prevent Alzheimer's Disease 2020, and former coordinator of Alzheimer's - related activities at the US National Institutes of Health.
There is a growing sense in the field — among academics and industry representatives alike — that these efforts are the last chance for the amyloid hypothesis.
According to the proposal, called the amyloid hypothesis, Alzheimer's disease, estimated to affect more than 5 million people in the United States alone, is caused by abnormal buildup of A-beta protein in the brain.
If the beta - amyloid hypothesis is correct, then the clinical trials we are doing right now might stop or prevent this disease.
According to this «amyloid hypothesis,» the protein forms plaques in the brain that damage and eventually destroy brain cells.
Yesterday, the National Institutes of Health (NIH) announced that it is giving $ 33 million to a study that researchers hope will either revive the amyloid hypothesis, or put it to bed.
According to Neil Buckholtz, director of the NIA Division of Neuroscience, the investment reflects a shift toward trying to prevent the disease before it ravages the brain, rather than reverse its effects, and a commitment to testing the amyloid hypothesis properly.
A planned clinical trial in people with high genetic risk of developing Alzheimer's will put the amyloid hypothesis to the test yet again
The amyloid hypothesis has been called into question in recent years as clinical trials with drugs and antibodies intended to reduce amyloid buildup in the brain have yielded disappointing results.
Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
This trial is a point in favour of the «amyloid hypothesis», which suggests that elimination of the protein itself might alleviate the disease's symptoms.
Experimental Alzheimer Drugs Targeting Beta - Amyloid and the «Amyloid Hypothesis.»
This drug safely lowers A-beta levels and allows the amyloid hypothesis to be put to the test.
John Hardy is a neurologist of University College London and is one of those responsible for the proposal of the amyloid hypothesis, and he says, «All the basic science work and natural history work supports it.»
The new hypothesis has been named the amyloid hypothesis.
Periodically we hear suggestions that the amyloid hypothesis, the basis of much research on Alzheimer's disease, is in trouble.
The approach, Erlanson adds, «has delivered a molecule with sufficiently good properties that Merck will be able to directly test the amyloid hypothesis for Alzheimer's disease.»